Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAC · 1 trial · 1 indication
To determine the iRR rate of 4 cycles of docetaxel, doxorubicin and cyclophosphamide (TAC) and of 4 cycles of vinorelbine and capecitabine (NX) (TAC-NX) as a salvage treatment
| Arm | Type | Description |
|---|---|---|
| resp: 4xTAC | EXPERIMENTAL | Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC |
| resp: 6xTAC | EXPERIMENTAL | Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC |
| nonResp: 4xTAC | EXPERIMENTAL | Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC |
| nonResp: 4xNX | EXPERIMENTAL | Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX |
| Name | Type | Description |
|---|---|---|
| TAC | DRUG | Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks |
| NX | DRUG | Vinorelbine 25 mg/m² as a \< 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks |
Inclusion Criteria: * Written informed consent must be obtained and documented according to the local regulatory requirements prior to beginning specific protocol procedures. * Complete baseline documentation sent to SKM CRS. * Unilateral or bilateral primary carcinoma of the breast, confirmed hist...
Top 20 of 92 competitors
TAC is a combination chemotherapy regimen used in breast cancer. It is being studied as preoperative treatment for patients with locally advanced or operable primary breast cancer. The regimen combines docetaxel, doxorubicin, and cyclophosphamide. It is currently in Phase 3 clinical development and is considered investigational.
TAC is a combination of three chemotherapy drugs: docetaxel, doxorubicin, and cyclophosphamide. These agents target rapidly dividing cancer cells by interfering with microtubule function, DNA replication, and cell division. The regimen is used in the treatment of breast cancer.
TAC is developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The company is conducting clinical trials to evaluate the regimen in breast cancer patients.
TAC is in Phase 3 clinical development. It is an investigational regimen and has not been approved by regulatory authorities. One Phase 3 trial has been completed, involving 2014 female patients aged 18 years and older with breast cancer.
TAC has one completed Phase 3 clinical trial, identified as NCT00544765. The trial compared docetaxel, doxorubicin, and cyclophosphamide versus vinorelbine and capecitabine in patients with locally advanced or operable primary breast cancer. The study enrolled 2014 participants and was completed.
Yes, TAC refers to the combination of docetaxel, doxorubicin, and cyclophosphamide. These three drugs are used together as a chemotherapy regimen for breast cancer. The regimen was evaluated in a Phase 3 clinical trial for preoperative treatment of breast cancer.